# TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

> **NCT05195060** · — · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 1178 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** casirivimab with imdevimab
- **DRUG:** sotrovimab
- **DRUG:** molnupiravir

## Key facts

- **NCT ID:** NCT05195060
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 1178 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195060, "TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05195060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*